Covetrus Inc
NASDAQ:CVET
Intrinsic Value
Covetrus, Inc. engages in developing technologies and services for animal health industry. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CVET.
Covetrus Inc's market capitalization is 2.9B USD.
CVET stock price is 20.99 USD.
CVET.
CVET. Open DCF Valuation
CVET. Open Relative Valuation
CVET.
CVET's Revenue has grown by 2% over the past 12 months.
CVET's ROE (Return on Equity) has decreased in the last 3 years from 0% to -1%, and is approaching profitability.
CVET's ROIC (Return on Invested Capital) has decreased in the last 3 years from 1% to 0%.
CVET has positive Free Cash Flow for the last twelve months.
CVET has positive Gross Profit for the last twelve months.
CVET's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to 0%.
CVET's ROE (Return on Equity) for the past 12 months is negative and is equal to -1%.
CVET's long-term assets (3B USD) exceed its long-term liabilties (2B USD).
CVET's Altman Z-Score is equal to 2.04.
CVET has negative Operating Income for the last twelve months.
CVET's short-term assets (1B USD) exceed its short-term liabilties (733m USD).
CVET's D/E (Debt to Equity) is very low and is equal to 0.65.
CVET has negative three-year average ROIC (Return on Invested Capital): -1%. The company is not efficient at using invested capital to generate operating income.
CVET has negative Net Income for the last twelve months.
CVET has positive Net Debt. This means that the company has more debt (983m USD) than cash and short-term investments (87m USD).
CVET has negative three-year average ROE (Return on Equity): -22%. The company is not efficient at transforming stockholders' equity into net income.
CVET doesn't generate enough operating income (-1m USD) to safely cover interest payments on its debt (22m USD).
Fundamental Analysis
Covetrus Inc
Balance Sheet Decomposition
Covetrus Inc
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 87m |
| Receivables | 656m |
| Other Current Assets | 635m |
| Non-Current Assets | 2B |
| Long-Term Investments | 45m |
| PP&E | 287m |
| Intangibles | 1.6B |
| Other Non-Current Assets | 40m |
| Current Liabilities | 733m |
| Accounts Payable | 446m |
| Accrued Liabilities | 58m |
| Other Current Liabilities | 229m |
| Non-Current Liabilities | 1.2B |
| Long-Term Debt | 983m |
| Other Non-Current Liabilities | 177m |
Earnings Waterfall
Covetrus Inc
|
Revenue
|
4.6B
USD
|
|
Cost of Revenue
|
-3.8B
USD
|
|
Gross Profit
|
882m
USD
|
|
Operating Expenses
|
-883m
USD
|
|
Operating Income
|
-1m
USD
|
|
Other Expenses
|
-12m
USD
|
|
Net Income
|
-13m
USD
|
Free Cash Flow Analysis
Covetrus Inc
What is Free Cash Flow?
CVET Profitability Score
Profitability Due Diligence
Covetrus Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Covetrus Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
CVET Solvency Score
Solvency Due Diligence
Covetrus Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Covetrus Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CVET Price Targets Summary
Covetrus Inc
Ownership
CVET Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CVET Price
Covetrus Inc
| Average Annual Return | 26.61% |
| Standard Deviation of Annual Returns | 122.22% |
| Max Drawdown | -83% |
| Market Capitalization | 2.9B USD |
| Shares Outstanding | 140 123 008 |
| Percentage of Shares Shorted | 4.21% |
Company Profile
Covetrus Inc
Country
Industry
Market Cap
Dividend Yield
Description
Covetrus, Inc. engages in developing technologies and services for animal health industry. The company is headquartered in Portland, Maine and currently employs 4,035 full-time employees. The company went IPO on 2019-02-04. The firm operates through three segments: North America, Europe, and Asia Pacific (APAC) & Emerging Markets. The firm's products and services include supply chain services, software services, and prescription management. The supply chain services offers a portfolio of products and services and value-added solutions for enhancing operating efficient practices and delivering animal care. Software services develops, provides, and supports veterinary practices with a range of veterinary software systems. This includes practice management software, data-driven applications, client communications tools, and related services. The prescription management platform, which integrates into veterinary practice management software and workflow, client engagement and outreach communications, and integrated veterinary-pharmacy services and is designed to improve medical compliance.
You don't have any saved screeners yet
